Cargando…

The Huntington's Disease-Related Cardiomyopathy Prevents a Hypertrophic Response in the R6/2 Mouse Model

Huntington's disease (HD) is neurodegenerative disorder for which the mutation results in an extra-long tract of glutamines that causes the huntingtin protein to aggregate. It is characterized by neurological symptoms and brain pathology that is associated with nuclear and cytoplasmic aggregate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mielcarek, Michal, Bondulich, Marie K., Inuabasi, Linda, Franklin, Sophie A., Muller, Thomas, Bates, Gillian P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182603/ https://www.ncbi.nlm.nih.gov/pubmed/25268775 http://dx.doi.org/10.1371/journal.pone.0108961

Ejemplares similares

Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease
por: Mielcarek, Michal, et al.
Publicado: (2014)

Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease
por: Bondulich, Marie Katrin, et al.
Publicado: (2021)

SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease
por: Mielcarek, Michal, et al.
Publicado: (2011)

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment
por: Pido-Lopez, Jeffrey, et al.
Publicado: (2019)

Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease
por: Benn, Caroline L., et al.
Publicado: (2009)

Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington’s disease mice
por: Bondulich, Marie K., et al.
Publicado: (2017)

HDAC4 Does Not Act as a Protein Deacetylase in the Postnatal Murine Brain In Vivo
por: Mielcarek, Michal, et al.
Publicado: (2013)

HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy
por: Mielcarek, Michal, et al.
Publicado: (2015)

Huntington's disease is a multi-system disorder
por: Mielcarek, Michal
Publicado: (2015)

The Ubiquitin-Proteasome Reporter GFPu Does Not Accumulate in Neurons of the R6/2 Transgenic Mouse Model of Huntington's Disease
por: Bett, John S., et al.
Publicado: (2009)

Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington's Disease Mouse Model
por: Mielcarek, Michal, et al.
Publicado: (2017)

Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease
por: Bobrowska, Anna, et al.
Publicado: (2011)

Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington’s disease
por: Landles, Christian, et al.
Publicado: (2012)

Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington’s disease
por: El-Akabawy, Gehan, et al.
Publicado: (2012)

Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington’s disease
por: Irvine, Elaine E., et al.
Publicado: (2019)

A shared mechanism of muscle wasting in cancer and Huntington’s disease
por: Mielcarek, Michal, et al.
Publicado: (2015)

Skeletal muscle pathology in Huntington's disease
por: Zielonka, Daniel, et al.
Publicado: (2014)

Prevention of Sudden Death in Hypertrophic Cardiomyopathy
por: Arteaga-Fernández, Edmundo, et al.
Publicado: (2018)

Preventative therapeutic approaches for hypertrophic cardiomyopathy
por: Solomon, Tanya, et al.
Publicado: (2020)

Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease
por: Sathasivam, Kirupa, et al.
Publicado: (2010)

Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/1 Mouse Model of Huntington’s Disease
por: Rattray, Ivan, et al.
Publicado: (2013)

Neuro-Cardio Mechanisms in Huntington’s Disease and Other Neurodegenerative Disorders
por: Critchley, Bethan J., et al.
Publicado: (2018)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Hypertrophic Cardiomyopathy
por: Butt, Asra K., et al.
Publicado: (2023)

Amyloidosis with phenotype of hypertrophic cardiomyopathy
por: Kuryła, Martyna, et al.
Publicado: (2023)

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
por: Vakrou, Styliani, et al.
Publicado: (2021)

Ex vivo 100 μm isotropic diffusion MRI-based tractography of connectivity changes in the end-stage R6/2 mouse model of Huntington’s disease
por: Manivannan, Ashwinee, et al.
Publicado: (2023)

Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington’s Disease
por: Osmand, Alexander P., et al.
Publicado: (2016)

Differing strategies for sudden death prevention in hypertrophic cardiomyopathy
por: Maron, Martin S, et al.
Publicado: (2023)

Alternative processing of human HTT mRNA with implications for Huntington’s disease therapeutics
por: Fienko, Sandra, et al.
Publicado: (2022)

The systolic paradox in hypertrophic cardiomyopathy
por: Haland, Trine F, et al.
Publicado: (2017)

The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy
por: Kittleson, Mark D, et al.
Publicado: (2021)

Progressive Impairment of Lactate-based Gluconeogenesis in the Huntington’s Disease Mouse Model R6/2
por: Nielsen, Signe Marie Borch, et al.
Publicado: (2015)

Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
por: Stücker, Sabrina, et al.
Publicado: (2017)

Hypertrophic Obstructive Cardiomyopathy
por: Cohen, Lawrence S.
Publicado: (1972)

The genetics of hypertrophic cardiomyopathy
por: Akhtar, Mohammed, et al.
Publicado: (2018)

Disopyramide for Hypertrophic Cardiomyopathy
por: Sanchez-Nadales, Alejandro, et al.
Publicado: (2019)

Striatal Pre-Enkephalin Overexpression Improves Huntington’s Disease Symptoms in the R6/2 Mouse Model of Huntington’s Disease
por: Bissonnette, Stéphanie, et al.
Publicado: (2013)

The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington’s Disease
por: Beaumont, Vahri, et al.
Publicado: (2014)

Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington’s Disease
por: Paldino, Emanuela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_793psor2tu4m5sp77m23ntpslq